- Home
- DEC vs ERAS Comparison
DEC vs ERAS Comparison
Compare DEC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEC
- ERAS
- Stock Information
- Founded
- DEC 2001
- ERAS 2018
- Country
- DEC United States
- ERAS United States
- Employees
- DEC N/A
- ERAS N/A
- Industry
- DEC
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- DEC
- ERAS Health Care
- Exchange
- DEC Nasdaq
- ERAS Nasdaq
- Market Cap
- DEC 613.5M
- ERAS 719.0M
- IPO Year
- DEC N/A
- ERAS 2021
- Fundamental
- Price
- DEC $16.19
- ERAS $2.60
- Analyst Decision
- DEC Strong Buy
- ERAS Strong Buy
- Analyst Count
- DEC 2
- ERAS 6
- Target Price
- DEC $19.50
- ERAS $6.08
- AVG Volume (30 Days)
- DEC 281.7K
- ERAS 1.7M
- Earning Date
- DEC 01-01-0001
- ERAS 11-12-2024
- Dividend Yield
- DEC 7.15%
- ERAS N/A
- EPS Growth
- DEC N/A
- ERAS N/A
- EPS
- DEC 3.00
- ERAS N/A
- Revenue
- DEC $699,472,000.00
- ERAS N/A
- Revenue This Year
- DEC $5.10
- ERAS N/A
- Revenue Next Year
- DEC $27.48
- ERAS N/A
- P/E Ratio
- DEC $5.41
- ERAS N/A
- Revenue Growth
- DEC N/A
- ERAS N/A
- 52 Week Low
- DEC $10.54
- ERAS $1.51
- 52 Week High
- DEC $17.10
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- DEC 84.87
- ERAS 41.83
- Support Level
- DEC $12.47
- ERAS $2.62
- Resistance Level
- DEC $13.50
- ERAS $2.97
- Average True Range (ATR)
- DEC 0.45
- ERAS 0.21
- MACD
- DEC 0.37
- ERAS -0.04
- Stochastic Oscillator
- DEC 94.51
- ERAS 11.32
About DEC Diversified Energy Company plc
Diversified Energy Co PLC is an independent owner and operator of producing natural gas and oil wells concentrated in the Appalachian Basin. The company acquires and manages gas and oil properties and certain associated midstream assets. Its operations are located throughout the neighboring states of Tennessee, Kentucky, Virginia, West Virginia, Ohio, Pennsylvania, Oklahoma, Texas, and Louisiana.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.